Ruth Gimeno, Ph.D.
Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development
Ruth Gimeno is Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development at Eli Lilly and Company leading research and early clinical development in diabetes, obesity and cardiometabolic disorders with responsibility from project initiation through the end of Phase 2. Under Ruth's leadership, Lilly has built a strong early-phase clinical pipeline focused on diabetes, obesity and cardiovascular disease, and advanced several innovative molecules into Phase 3 and to the market, including BIF, a novel weekly basal insulin (in phase 3), Lyumjev, an ultrarapid insulin lispro formulation, and tirzepatide, a first-in-class GIP and GLP-1 receptor agonist. Prior to joining Lilly in 2011, Ruth led research teams focused on metabolic disease drug discovery at Millennium Pharmaceuticals, Wyeth and Pfizer.
Ruth received undergraduate training in medicine at the Julius-Maximilians-University in Würzburg, Germany, and obtained a Ph.D. in biology from the Massachusetts Institute of Technology in Cambridge, USA.
